Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status

Early this month, the FDA handed Junshi Biosciences an agency first: A breakthrough designation for a PD-(L)1 therapy out of China. Now, the Shanghai-based biotech is declaring pivotal success.